METHOD OF THE COMBINED TREATMENT OF METASTATIC COLORECTAL CANCER IN PATIENTS WITH RESECTABLE LIVER METASTASES IN THE PRESENCE OF MUTATIONS IN THE KRAS GENES Russian patent published in 2023 - IPC A61B17/00 A61K31/4375 A61K31/282 A61K39/395 A61P35/00 

FIELD: medicine; oncology.

SUBSTANCE: invention can be used as a combined treatment of metastatic colorectal cancer in patients with resectable liver metastases in the presence of mutations in the KRAS genes. The method includes courses of antitumor drug therapy using irinotecan at a dose of 165 mg/m² intravenously by drop infusions on day 1, oxaliplatin at a dose of 85 mg/m² intravenously by drop infusions on day 1, capecitabine orally daily in two doses. 3 courses of preoperative treatment according to the above scheme, radical surgery and 3 courses of adjuvant treatment are applied. Capecitabine at a dose of 2,500 mg/m² is administered within days 1 to 14, bevacizumab at a dose of 5 mg/kg of body weight is administered intravenously by drop infusions on day 1 with the interval between courses equal to 7 days.

EFFECT: use of the invention improves the results of combined treatment of metastatic colorectal cancer in patients with resectable liver metastases in the presence of mutations in the KRAS genes by increasing the frequency of objective tumor responses and reducing the number of adverse events during antitumor drug treatment, increasing the frequency of performing parenchyma-sparing radical liver resections, and also increasing the overall and relapse-free survival of patients.

1 cl, 2 ex